Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit

NCT02516553 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02516553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02516553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
July 8, 2015
Completion date
November 23, 2021
Enrollment
174 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, nut carcinoma